VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.

VNRX has been the subject of several other reports. Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com assumed coverage on VolitionRx in a research report on Thursday. They set a “sell” rating for the company.

VolitionRx Price Performance

Shares of VNRX stock traded down $0.01 on Thursday, hitting $0.55. 11,446 shares of the company’s stock were exchanged, compared to its average volume of 178,448. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.02. The stock has a market cap of $50.50 million, a P/E ratio of -1.51 and a beta of 1.09. The company has a 50 day moving average of $0.60 and a 200 day moving average of $0.64.

Hedge Funds Weigh In On VolitionRx

Several large investors have recently bought and sold shares of the company. Lagoda Investment Management L.P. raised its position in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares during the period. Northern Trust Corp increased its stake in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares during the period. Millennium Management LLC acquired a new stake in VolitionRx during the fourth quarter worth approximately $36,000. Finally, Two Sigma Securities LLC acquired a new stake in VolitionRx during the fourth quarter worth approximately $29,000. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.